Abstract: The present invention provides a method for promoting functional cure of AIDS by reducing HIV reservoir with lenalidomide, the method including administering a therapeutically effective amount of lenalidomide to a patient. Also provided is a method for reducing intracellular P24 and cell-related HIV RNA in PBMCs derived from HIV patients in vitro with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks. Further provided is a method for inhibiting latent activator-induced activation of latent HIV cell line U1 with lenalidomide, including orally administering lenalidomide at 25 mg/d at days 1 to 21 in a 28-day cycle, and continuing ART for 48 weeks.

Abstract: A novel purified phosphoprotein designated mitosin is provided by this invention. Also provided is the amino acid sequence of mitosin, active fragments of mitosin, and a nucleic acid molecule encoding mitosin. Diagnostic and therapeutic methods of using the protein and nucleic acid molecule are also provided. The nucleic acid molecules are useful to recombinantly produce mitosin and for use as probes. The compositions and methods of this invention are based on the discovery that the intracellular presence of mitosin is necessary for the cell to enter the M phase of mitosis, and that the degradation of mitosin is necessary for the cell to advance to the next stage. Thus, an anti-mitsoin antibody, or a mutant or non-functional analog of mitosin, would inhibit the mitotic cell cycle by preventing cells from entering the M phase, and overexpression of mitosin, or a functional equivalent thereof, would inhibit the cycle by preventing cells from leaving the M phase.